Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ValiRx has raised £1.15mln via a share placing to accelerate its clinical and pre-clinical portfolio

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities
Cancer cells
ValiRx said the net proceeds will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer

ValiRx PLC (LON:VAL), the clinical stage biotechnology company, has raised £1.15mln via a placing to accelerate its clinical and pre-clinical portfolio, welcoming new investors in the process.

The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities.

WATCH: Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

The group said the net proceeds of the placing will be used to extend and expand the scope of the clinical trial of VAL201 to treat prostate cancer and to thereby allow the treatment to more speedily reach its full therapeutic potential and potential anti-cancer impact. 

It added that the funds will also be used to progress the development of the pre-clinical VAL301 and VAL101 programmes and towards clinical trials.

Dr Satu Vainikka, ValiRx’s CEO commented: "I am grateful for the support we have received from both new and existing investors and their investment will enable the Company to further progress and accelerate its clinical and pre-clinical portfolio, namely VAL101, 201 and 301 and move these therapeutic assets closer to their respective value inflection points".

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Pharmaceuticals
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
researcher filling a vial
July 16 2018
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use